Savara to Host Call on Phase 3 IMPALA-2 Trial Results of Molgramostim for aPAP

LANGHORNE, Pa.-- Savara Inc. (Nasdaq: SVRA), a company specializing in the treatment of rare respiratory diseases, has announced a forthcoming conference call and webcast scheduled for tomorrow, Wednesday, June 26, 2024, at 8:00 am ET. The purpose of this event is to discuss the primary results of the Phase 3 IMPALA-2 clinical trial, which evaluates the effectiveness and safety of molgramostim, an inhaled version of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), in patients diagnosed with autoimmune pulmonary alveolar proteinosis (aPAP). Before the conference call begins, the company intends to release a press statement detailing the top-line results at around 6:30 am ET.

For those interested in joining the live webcast of the conference call, access is provided through a specific link or via the "Events & Presentations" section of Savara's website. Participants who prefer to join by phone can register through a dedicated link to receive dial-in details. An archived replay of the webcast will be available about 24 hours after the call concludes and will remain accessible for 90 days in the "Events & Presentations" section on the company's website.

Savara Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for rare respiratory conditions. Their foremost project is the molgramostim nebulizer solution, an inhalable GM-CSF, currently in Phase 3 trials for treating autoimmune pulmonary alveolar proteinosis (aPAP). This treatment is administered using an investigational eFlow® Nebulizer System developed by PARI Pharma GmbH. The management team at Savara possesses extensive expertise in rare respiratory illnesses and pulmonary medicine, with a proven track record in identifying unmet medical needs and advancing product candidates from development through to approval and commercial distribution.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!